Literature DB >> 2028435

Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis.

A Wollner1, J Mohle-Boetani, R E Lambert, J L Perruquet, T A Raffin, J L McGuire.   

Abstract

Low dose methotrexate has been used effectively for various rheumatic and non-rheumatic diseases. Three cases of Pneumocystis carinii pneumonia occurring during treatment of rheumatoid arthritis with low dose methotrexate are presented. Several mechanisms might contribute to impaired immunity and the rare development of opportunist lung infection with methotrexate. A high degree of suspicion may result in earlier diagnosis and treatment.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2028435      PMCID： PMC463037          DOI： 10.1136/thx.46.3.205

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  12 in total

1.  Rheumatoid arthritis, methotrexate therapy, and Pneumocystis pneumonia.

Authors:  R L Leff; J P Case
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

2.  Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

3.  A study of the distribution of methotrexate in human tissues and tumors.

Authors:  L L Anderson; G J Collins; Y Ojima; R D Sullivan
Journal:  Cancer Res       Date:  1970-05       Impact factor: 12.701

4.  Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis.

Authors:  J L Perruquet; T M Harrington; D E Davis
Journal:  Arthritis Rheum       Date:  1983-10

5.  Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis.

Authors:  W C Noble; P M White; H Baker
Journal:  J Invest Dermatol       Date:  1975-02       Impact factor: 8.551

Review 6.  Pulmonary disease in the immunocompromised host (2).

Authors:  W R Wilson; F R Cockerill; E C Rosenow
Journal:  Mayo Clin Proc       Date:  1985-09       Impact factor: 7.616

7.  Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms.

Authors:  D B Hellmann; M Petri; Q Whiting-O'Keefe
Journal:  Medicine (Baltimore)       Date:  1987-09       Impact factor: 1.889

8.  Immunologic studies of rheumatoid arthritis patients treated with methotrexate.

Authors:  N J Olsen; L F Callahan; T Pincus
Journal:  Arthritis Rheum       Date:  1987-05

Review 9.  Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature.

Authors:  G D Groff; K N Shenberger; W S Wilke; T H Taylor
Journal:  Semin Arthritis Rheum       Date:  1983-05       Impact factor: 5.532

10.  Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy.

Authors:  S L Morgan; J E Baggott; M Altz-Smith
Journal:  Arthritis Rheum       Date:  1987-12
View more
  11 in total

1.  Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area.

Authors:  J Hamilton; I B McInnes; E A Thomson; D Porter; J A Hunter; R Madhok; H A Capell
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma.

Authors:  T R Shulimzon; R J Shiner
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 3.  Corticosteroid sparing agents in asthma.

Authors:  J M Hill; A E Tattersfield
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 4.  Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.

Authors:  F Salaffi; P Manganelli; M Carotti; S Subiaco; G Lamanna; C Cervini
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

Review 5.  Methotrexate-related pulmonary complications in rheumatoid arthritis.

Authors:  P Barrera; R F Laan; P L van Riel; P N Dekhuijzen; A M Boerbooms; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

Review 6.  Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.

Authors:  James A Grubbs; John W Baddley
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

7.  Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study.

Authors:  Shin-Ichiro Ohmura; Yoichiro Homma; Takayuki Masui; Toshiaki Miyamoto
Journal:  Intern Med       Date:  2021-09-11       Impact factor: 1.282

8.  Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.

Authors:  L M Kuitert; A C Harrison
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

Review 9.  Histopathological Features of Methotrexate Induced Pulmonary Lesions in Rheumatoid Arthritis Patients: A Systematic Review of Case Reports.

Authors:  Anthony Thaniyan; Foad F A Ayman; Hyder O Mirghani; Badr A Al-Sayed; Tarig H Merghani
Journal:  Open Access Maced J Med Sci       Date:  2017-04-08

10.  Increasing Pneumocystis pneumonia, England, UK, 2000-2010.

Authors:  Rishma Maini; Katherine L Henderson; Elizabeth A Sheridan; Theresa Lamagni; Gordon Nichols; Valerie Delpech; Nick Phin
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.